BCAL Diagnostics Partners with ClearNote to Deliver Advanced Cancer Detection in Australia and New Zealand.

BCAL Diagnostics Limited (ASX: BDX) has entered an exclusive licence agreement with US-based ClearNote Health to bring its advanced Avantect pancreatic and ovarian cancer blood tests to Australia and New Zealand. The collaboration expands BCAL’s oncology portfolio, complementing its breast cancer test program with highly validated, non-invasive diagnostic solutions for cancers that are typically detected late and are difficult to treat. ClearNote’s proprietary epigenomics-based platform, supported by global clinical validation and AI-driven bioinformatics, underpins these breakthrough tests.

BCAL will integrate the assays into its established distribution network, including key diagnostic partners such as Cancer Care and Associates and Sydney Breast Clinic. With pancreatic and ovarian cancers responsible for approximately 5,000 Australian deaths annually, this partnership positions BCAL to lead in early detection and broaden its reach across multiple cancer types. The initial agreement runs for two years from Q1 CY26, with an option to extend for an additional six years.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com